Hosted on MSN1mon
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
Regor’s most advanced orally-administered CDK4/2 inhibitor in the clinic, RGT-419B, will be added to Roche’s pipeline. RGT-419B is a potent CDK4 inhibitor with increased activity on CDK2 ...
pharmaphorum1mon
Genentech buys Regor's next-gen CDK inhibitors for $850M
Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash ...